Neuropathology of progressive supranuclear palsy after treatment with tilavonemab

Volume: 20, Issue: 10, Pages: 786 - 787
Published: Oct 1, 2021
Abstract
We read with interest the Article by Günter Höglinger and colleagues reporting the results of a phase 2, randomised, placebo-controlled trial of tilavonemab for patients with progressive supranuclear palsy.1Höglinger GU Litvan I Mendonca N et al.Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.Lancet Neurol. 2021; 20: 182-192Summary Full Text Full Text PDF PubMed Scopus (20)...
Paper Details
Title
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab
Published Date
Oct 1, 2021
Volume
20
Issue
10
Pages
786 - 787
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.